by British Medical Journal A new study published by The BMJ today adds to evidence that rosiglitazone—a drug used to treat type 2 diabetes—is associated with an increased risk of heart problems, especially heart failure. This study is the most comprehensive evaluation of the cardiovascular risk of rosiglitazone ever done. Rosiglitazone belongs to a class...